POAI dividend history
Predictive Oncology Inc. (POAI) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common StockEAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) ("Predictive Oncology" or the "Company"), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on March 27, 2023. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on March 27, 2023. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusi
- Predictive Oncology Reports Year End 2021 Financial Results and Provides Business UpdateEAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence ("AI") to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2021, a period defined by growth, expansion and maturity, and provided an update on business activities. 2021 Highlights: Validated results of subsidiary Helomics' Discovery 21 proof of concept of its PeDAL® platform, demonstrated ability to make high-confidence predictions in ovarian tumor samples.Added new revenue stream, synergistic customer base and disruptive technology through acquisition of zPREDICTA, Inc., a comp
- Predictive Oncology Reports Third Quarter Financial ResultsEAGAN, Minn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (NASDAQ:POAI) today, announcing financial results for the quarter ended September 30, 2021. All three of Predictive Oncology's reportable segments recognized revenue for the quarter, and the loss per common share was reduced to $0.08, compared to $0.46 for the same period in 2020. The knowledge-driven company, which is applying artificial intelligence ("AI") to personalized medicine and drug discovery, also provided an update on its business activities. Highlights from the quarter include: Net increase in cash and equivalents amounting to $41 mi